登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C22H22N6O7S2 · 5H2O
化学文摘社编号:
分子量:
636.65
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24
SMILES string
[s]1c(nc(c1)\C(=N\OC(C)(C)C(=O)[O-])\C(=O)N[C@H]2[C@H]3SCC(=C(N3C2=O)C(=O)O)C[n+]4ccccc4)N.O.O.O.O.O
InChI
1S/C22H22N6O7S2.5H2O/c1-22(2,20(33)34)35-26-13(12-10-37-21(23)24-12)16(29)25-14-17(30)28-15(19(31)32)11(9-36-18(14)28)8-27-6-4-3-5-7-27;;;;;/h3-7,10,14,18H,8-9H2,1-2H3,(H4-,23,24,25,29,31,32,33,34);5*1H2/b26-13-;;;;;/t14-,18-;;;;;/m1...../s1
InChI key
NMVPEQXCMGEDNH-TZVUEUGBSA-N
grade
pharmaceutical primary standard
API family
ceftazidime
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Ceftazidime EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Resp. Sens. 1 - Skin Sens. 1
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Anu Kantele et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 60(6), 837-846 (2015-01-24)
More than 300 million travelers visit regions with poor hygiene annually. A significant percentage of them become colonized by resistant intestinal bacteria such as extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) and may transmit the strains to others and to medical care settings
Johanna Berkhout et al.
Antimicrobial agents and chemotherapy, 59(2), 1138-1144 (2014-12-10)
To evaluate the in vitro effects of the combination of ceftazidime and avibactam on the MICs of both compounds, checkerboard assays were performed for 81 clinical strains, including 55 Enterobacteriaceae strains (32 Klebsiella pneumoniae, 19 Escherichia coli, 1 Citrobacter freundii
S Segal-Maurer et al.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 28(5), 1134-1138 (1999-08-19)
Increasing prevalence of multidrug-resistant gram-negative organisms has led to a rise in clinically significant infections with these organisms and an increasing therapeutic dilemma. We present a case of a neurosurgical patient who developed ventriculoperitoneal shunt-associated ventriculitis due to ceftazidime-resistant Klebsiella
Jason A Roberts et al.
International journal of antimicrobial agents, 29(2), 117-128 (2006-12-13)
Sepsis and nosocomial infections continue to be a significant problem in intensive care, contributing heavily to mortality and prolonged hospital stay. Early and appropriate antibiotic therapy is critical for optimising outcomes. However, the emergence of highly resistant bacteria, coupled with
A Walkty et al.
Antimicrobial agents and chemotherapy, 57(11), 5707-5709 (2013-08-14)
The in vitro activity of ceftolozane in combination with tazobactam (fixed concentration of 4 μg/ml) was evaluated against 2,435 Pseudomonas aeruginosa clinical isolates obtained from across Canada using Clinical and Laboratory Standards Institute broth microdilution methods. The MIC50 and MIC90
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持